hepatoblastoma (Cancer)
Information
- Disease name
- hepatoblastoma
- Disease ID
- DOID:687
- Description
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| RINT1 | 7 | 105,532,201 | 105,567,677 | 2 |
| EZH2 | 7 | 148,807,383 | 148,884,291 | 2 |
| RAD51B | 14 | 67,819,779 | 68,611,565 | 2 |
| TSHR | 14 | 80,955,043 | 81,146,302 | 2 |
| RAD50 | 5 | 132,556,977 | 132,646,349 | 2 |
| ATR | 3 | 142,449,235 | 142,578,733 | 2 |
| APC | 5 | 112,737,885 | 112,846,239 | 2 |
| MC1R | 16 | 89,914,847 | 89,920,951 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05302921 | Active, not recruiting | Phase 2 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | February 18, 2022 | July 1, 2025 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT02867592 | Active, not recruiting | Phase 2 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | May 18, 2017 | September 21, 2024 |
| NCT03017326 | Active, not recruiting | Phase 3 | Paediatric Hepatic International Tumour Trial | August 24, 2017 | August 1, 2027 |
| NCT03220035 | Active, not recruiting | Phase 2 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | November 8, 2017 | September 22, 2024 |
| NCT03533582 | Active, not recruiting | Phase 2/Phase 3 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | May 24, 2018 | June 30, 2026 |
| NCT05693519 | Active, not recruiting | GastroIntestinal Cancer in Children and Adolescents | December 22, 2022 | June 22, 2023 | |
| NCT06190574 | Completed | Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma | July 30, 2021 | November 30, 2023 | |
| NCT02390843 | Completed | Phase 1 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | February 2015 | September 22, 2019 |
| NCT01125800 | Completed | Phase 1/Phase 2 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | February 2011 | October 2014 |
| NCT05763173 | Completed | Evaluation of Lung Metastases Based on Ultrashort Echo Time MRI | January 1, 2023 | February 29, 2024 | |
| NCT01154816 | Completed | Phase 2 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | February 2011 | June 30, 2019 |
| NCT05245123 | Completed | Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families | February 21, 2022 | March 31, 2023 | |
| NCT01331135 | Completed | Phase 1 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | April 2011 | August 9, 2017 |
| NCT01505569 | Completed | N/A | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | October 20, 2011 | February 1, 2024 |
| NCT03645655 | Completed | PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants | October 1, 2018 | June 30, 2021 | |
| NCT06198296 | Not yet recruiting | Phase 1 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | January 1, 2026 | February 1, 2043 |
| NCT03959800 | Recruiting | Molecular Basis of Pediatric Liver Cancer | June 22, 2015 | June 30, 2029 | |
| NCT02557750 | Recruiting | Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience | January 2016 | October 2023 | |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT04308330 | Recruiting | Phase 1 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | March 17, 2017 | December 31, 2024 |
| NCT04337177 | Recruiting | Phase 1 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | October 25, 2021 | June 2024 |
| NCT04478292 | Recruiting | Phase 3 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | March 1, 2021 | September 30, 2027 |
| NCT04634357 | Recruiting | Phase 1/Phase 2 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma | July 19, 2022 | January 31, 2028 |
| NCT04897321 | Recruiting | Phase 1 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | July 6, 2022 | March 1, 2027 |
| NCT04315883 | Terminated | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | February 11, 2021 | March 28, 2024 | |
| NCT05170282 | Unknown status | Deep Learning Magnetic Resonance Imaging Radiomics for Diagnostic Value of Hepatic Tumors in Infants | January 1, 2021 | December 31, 2023 | |
| NCT05322187 | Unknown status | Phase 2/Phase 3 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy | April 10, 2022 | December 31, 2023 |
| NCT00179816 | Unknown status | Phase 1/Phase 2 | Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | April 1999 | September 2012 |
| NCT02933333 | Unknown status | Phase 4 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | September 27, 2016 | December 2020 |
| NCT04093648 | Withdrawn | Phase 1 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | January 2020 | January 2038 |
| NCT00228683 | Withdrawn | N/A | Hepatoblastoma Biology Study and Tissue Bank | September 2005 | January 2015 |
| NCT02011126 | Withdrawn | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | June 30, 2014 |
- Disase is a (Disease Ontology)
- DOID:3571
- Cross Reference ID (Disease Ontology)
- GARD:2657
- Cross Reference ID (Disease Ontology)
- ICD10CM:C22.2
- Cross Reference ID (Disease Ontology)
- ICDO:8970/3
- Cross Reference ID (Disease Ontology)
- MESH:D018197
- Cross Reference ID (Disease Ontology)
- NCI:C3728
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:109843000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206624
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002884
- OrphaNumber from OrphaNet (Orphanet)
- 449
- ICD10 preferred id (Insert disease from ICD10)
- D0001915
- ICD10 class code (Insert disease from ICD10)
- C22.2
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018197